title: Use of biologics in SLE: a review of the evidence from a clinical perspective.
abstract: With the explosion in biologics use in rheumatology, newer and smarter ways of using these drugs in different diseases have been advocated. SLE has to date been at the back of the biologics algorithms. Recently, the US Food and Drug Administration and European Medicines Evaluation Agency licensed belimumab for use in SLE, the first drug in >30 years. A clinical review of the evidence that underlies the use of belimumab and other biologics in SLE reveals possible reasons why the results are not as spectacular as they are in other diseases.
authors.affiliation: Faculty of Health and Medicine, Lancaster University, and.
authors.forename: Jayoti
authors.initials: J
authors.lastname: Aytan
authors.affiliation: Faculty of Health and Medicine, Lancaster University, and Department of Rheumatology, University Hospitals of Morecambe Bay NHS Foundation Trust, Royal Lancaster Infirmary, Lancaster, UK marwan.bukhari@mbht.nhs.uk.
authors.forename: Marwan A S
authors.initials: MA
authors.lastname: Bukhari
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D001688:Biological Products / Q000627:therapeutic use*; D019317:Evidence-Based Medicine / Q000379:methods; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy*; D018579:Patient Selection
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D001688:Biological Products; D007166:Immunosuppressive Agents; C511911:belimumab
keywords: biologics; lupus; review